Genmab A/S

LSE:0MGB Stock Report

Market Cap: DKK 94.4b

Genmab Past Earnings Performance

Past criteria checks 4/6

Genmab has been growing earnings at an average annual rate of 10.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 23.8% per year. Genmab's return on equity is 14.7%, and it has net margins of 23.7%.

Key information

10.2%

Earnings growth rate

10.0%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate23.8%
Return on equity14.7%
Net Margin23.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Genmab makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

LSE:0MGB Revenue, expenses and earnings (DKK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2419,8444,7023,4759,032
30 Jun 2419,0165,5403,4708,773
31 Mar 2417,7835,4673,4788,189
31 Dec 2316,4744,3523,2977,630
30 Sep 2316,8524,1633,2847,285
30 Jun 2316,2274,6413,0946,683
31 Mar 2315,2205,1972,9006,112
31 Dec 2214,5055,4522,6765,524
30 Sep 2211,9875,6542,2675,219
30 Jun 2210,2103,9621,9034,847
31 Mar 229,0202,3771,5344,486
31 Dec 218,4172,9571,2834,181
30 Sep 217,9072,8731,0023,787
30 Jun 217,3212,5138413,394
31 Mar 2110,8005,5857563,248
31 Dec 2010,1114,7586613,137
30 Sep 2011,0285,6495462,880
30 Jun 2010,3445,6564832,766
31 Mar 205,6672,3633772,555
31 Dec 195,3662,1663422,386
30 Sep 193,6411,5282852,173
30 Jun 193,1991,1702581,910
31 Mar 192,9351,3452411,664
31 Dec 183,0251,4722141,431
30 Sep 182,8071,4241951,227
30 Jun 182,5321,2391771,112
31 Mar 182,7961,286157995
31 Dec 172,3651,104147852
30 Sep 172,2751,159131795
30 Jun 172,3161,354121718
31 Mar 171,8971,215110704
31 Dec 161,8161,187102661
30 Sep 161,463735101642
30 Jun 161,37668694606
31 Mar 161,19653593529
31 Dec 151,13376491488
30 Sep 1577444392443
30 Jun 1576846390441
31 Mar 1571042086459
31 Dec 1485030180506
30 Sep 1485129277517
30 Jun 1472913872534
31 Mar 1475113869545
31 Dec 136647067528

Quality Earnings: 0MGB has high quality earnings.

Growing Profit Margin: 0MGB's current net profit margins (23.7%) are lower than last year (24.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 0MGB's earnings have grown by 10.2% per year over the past 5 years.

Accelerating Growth: 0MGB's earnings growth over the past year (12.9%) exceeds its 5-year average (10.2% per year).

Earnings vs Industry: 0MGB earnings growth over the past year (12.9%) exceeded the Biotechs industry -18.2%.

Return on Equity

High ROE: 0MGB's Return on Equity (14.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 09:53
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genmab A/S is covered by 45 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew CarlsenABG Sundal Collier
Armelle MoulinAlphaValue
Emily FieldBarclays